Abbott Laboratories vs. Minerva Neurosciences, Inc
Abbott Laboratories (ABT) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ABT | NERV | |
|---|---|---|
| Market Cap | $182.49 billion | $188.22 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-415,074,589 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | NERV | |
|---|---|---|
| P/E Ratio | 34.21 | — |
| Price / Book | 3.53 | -0.74 |
| Price / Sales | 3.92 | — |
NERV leads on 1 of 1 valuation factors.
Profitability
| ABT | NERV | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | 163.41% |
NERV leads on 1 of 1 profitability factors.
Risk & Sentiment
| ABT | NERV | |
|---|---|---|
| Short Interest | 0.57% | 3.60% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, NERV overview, NERV financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.